Atai Life Sciences ATAI and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).Patients were given an 8 mg dose of BPL-003 followed by a 12 mg dose two weeks later.Key FindingsFollowing the first (8 mg) dose, patients experienced a mean MADRS (Montgomery-Asberg Depression Rating Scale) reduction of ...

公司业务聚焦 - 百时美施贵宝的细胞疗法业务目前主要聚焦于血液学领域 [1] - 细胞疗法业务由公司高管Lynelle负责 其职务为细胞疗法业务负责人 [1] 行业发展趋势 - 细胞治疗领域已取得部分验证成果 同时存在大量创新机会 [2] - 该领域未来发展潜力巨大 行业前景令人振奋 [2]

EPS of -$0.24 significantly missed the expected $1.19, indicating financial challenges.Revenue of approximately $40.3 million fell short of the estimated $114.7 million.Despite the earnings miss, a solid cash position and strategic decisions provide a foundation for future operations and flexibility.On September 22, 2025, GENFIT SA (NASDAQ:GNFT) reported its earnings, revealing an EPS of -$0.24, which was significantly below the expected $1.19. The company's revenue was approximately $40.3 million, falling ...

Arquitos Capital Management, an investment management firm, released its second-quarter 2025 investor letter. During the period, the fund delivered a net return of 13.1%, bringing year-to-date gains to an impressive 28.8% as of June 30, 2025. The firm highlighted that individual investor returns may differ depending on the timing of capital inflows, and encouraged clients to review their statements for personalized results. In addition, you can check the fund’s top 5 holdings to find out its best picks for ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Through (TPT) payment status for Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s next-generation PSMA-PET1 imaging agent for prostate cancer. This designation enables separate reimbursement for Gozellix® under the ...

WOBURN, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), has engaged Lytham Partners to lead a strategic investor relations and shareholder communication program. For more than 20 years, Lytham Partners has been one of the country's leading investor relations firms, having created one of the industry's largest and most diverse networks of ...

Highly secure, institutional-grade infrastructure supports Bitcoin, Ethereum and Solana treasury strategySARASOTA, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that it has engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as custodian for its institutional crypto treasury platform. “O ...

Accessibility StatementSkip Navigation PHILADELPHIA, Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022(the "Class Period"). Investor Deadline: Investors who purchased or acquired Spectrum securities during the Class Pe ...

WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need. Peer-reviewed studies such as the ones published in Sci Trans Med, Clin Mic ...

MIAMI, FL, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced a successful meeting with FDA providing regulatory clarity for enobosarm, a selective androgen receptor modulator, as a muscle preservation drug product candidate in combination with GLP-1 RA for greater weight loss for the treatment of obesity. Highlights from FDA mee ...